Peptide-siRNA nanocomplexes targeting NF-κB subunit p65 suppress nascent experimental arthritis

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4363-4374

  Zhou, Hui Fang ^a   Yan, Huimin ^a   Pan, Hua ^a   Hou, Kirk K ^a   Akk, Antonina ^a   Springer, Luke E ^a   Hu, Ying ^a   Allen, J Stacy ^a   Wickline, Samuel A ^a   Pham, Christine T N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MELITTIN; MELITTIN DERIVED CATIONIC AMPHIPATHIC PEPTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOCOMPOSITE; NFKB1 PROTEIN, MOUSE; PEPTIDE; RELA PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE EROSION; CARTILAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SAFETY; EXPERIMENTAL ARTHRITIS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; CD4+ T LYMPHOCYTE; CHEMISTRY; COMPLEMENT ACTIVATION; CYTOLOGY; DISEASE MODEL; FLUORESCENCE MICROSCOPY; GENETICS; INFLAMMATION; MACROPHAGE; METABOLISM; NANOTECHNOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, RHEUMATOID; CARTILAGE; CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENT ACTIVATION; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION; MACROPHAGES; MICE; MICROSCOPY, FLUORESCENCE; NANOCOMPOSITES; NANOPARTICLES; NANOTECHNOLOGY; NF-KAPPA B P50 SUBUNIT; PEPTIDES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84907482356     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75673     Document Type: Article

References (44)

1. Pasparakis M. Regulation of tissue homeostasis by NF-κB signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009;9(11):778-788.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
3. Szekanecz Z, Besenyei T, Paragh G, Koch AE. New insights in synovial angiogenesis. Joint Bone Spine. 2009;77(1):13-19.
4. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):299-306.
5. Agarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm. 2011;17(9):S14-S18.
6. Buch MH, Bingham SJ, Bryer D, Emery P. Longterm infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 2007;46(7):1153-1156.
7. Feist E, Burmester GR. Small molecules targeting JAKs-a new approach in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013;52(8):1352-1357.
8. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford). 2008;47(5):584-590.
9. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factorkappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):212.
10. Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40/NF-κB signaling pathway in disease pathogenesis. Immunol Rev. 2010;233(1):55-61.
11. Van Loo G, Beyaert R. Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis. Arthritis Res Ther. 2011;13(3):221.
12. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132(3):344-362.
13. Hou KK, Pan H, Lanza GM, Wickline SA. Melittin derived peptides for nanoparticle based siRNA transfection. Biomaterials. 2013;34(12):3110-3119.
14. Hou KK, Pan H, Ratner L, Schlesinger PH, Wickline SA. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. AC S Nano. 2013;7(10):8605-8615.
15. Sessa G, Freer JH, Colacicco G, Weissmann G. Interaction of alytic polypeptide, melittin, with lipid membrane systems. J Biol Chem. 1969;244(13):3575-3582.
16. Pan H, et al. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J. 2010;24(8):2928-2937.
17. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283(5748):666-668.
18. Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med. 1985;162(6):1878-1891.
19. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with monoclonal antibodies to collagen. J Immunol. 1992;148(7):2103-2108.
20. Naeye B, et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials. 2013;34(9):2350-2358.
21. Pham CT, et al. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem. 2011;286(1):123-130.
22. Pham CT, et al. Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles. Nanomedicine. 2014;10(3):651-660.
23. Godl K, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A. 2003;100(26):15434-15439.
24. Davidson BL, McCray PB, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329-340.
25. Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Ar thritis Rheum. 2005;52(4):1314-1318.
26. Khoury M, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 2006;54(6):1867-1877.
27. Khoury M, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum. 2008;58(8):2356-2367.
28. Zhang T, Bai X, Mao X. Systemic delivery of small interfering RNA targeting the interleukin-2/15 receptor β chain prevents disease progression in experimental arthritis. PLoS One. 2013;8(11):e78619.
29. Lee SJ, et al. TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol Ther. 2014;22(2):397-408.
30. Duan J, et al. Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis. Nanomedicine (Lond). 2014;9(6):789-801.
31. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100-109.
32. Soenen SJ, Brisson AR, De Cuyper M. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials. 2009;30(22):3691-3701.
33. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-138.
34. Plank C, Mechtler K, Szoka FC, Szoka FC Jr, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7(12):1437-1446.
35. Sevast'ianov VI, Tseytlina EA. The activation of the complement system by polymer materials and their blood compatibility. J Biomed Mater Res. 1984;18(9):969-978.
36. Moghimi SM, Andersen AJ, Ahmadvand D, Wibroe PP, Andresen TL, Hunter AC. Material properties in complement activation. Adv Drug Deliv Rev. 2011;63(12):1000-1007.
37. Pan H, et al. Postformulation peptide drug loading of nanostructures. Methods Enzymol. 2012;508:17-39.
38. Pan H, et al. Programmable nanoparticle functionalization for in vivo targeting. FASEB J. 2013;27(1):255-264.
39. Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Le tt. 2008;8(4):1131-1136.
40. Soman NR, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009;119(9):2830-2842.
41. Leuschner F, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol. 2011;29(11):1005-1010.
42. Zhou HF, Chan HW, Wickline SA, Lanza GM, Pham CT. Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J. 2009;23(9):2978-2985.
43. Zhou HF, Hu G, Wickline SA, Lanza GM, Pham CT. Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond). 2010;5(7):1065-1074.
44. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophilderived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest. 2002;109(3):363-371.